US Patent

US9662338 — Formulations of viloxazine

Formulation · Assigned to Supernus Pharmaceuticals Inc · Expires 2035-04-02 · 9y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent discloses modified release formulations of viloxazine hydrochloride and methods of administering them, including high-drug load formulations.

USPTO Abstract

Modified release formulations of viloxazine and methods of administering the same are disclosed. High-drug load formulations of viloxazine are further disclosed.

Drugs covered by this patent

viloxazine-hydrochloride (VILOXAZINE HYDROCHLORIDE)

Patent Metadata

Patent number: US9662338
Jurisdiction: US
Classification: Formulation
Expires: 2035-04-02
Drug substance claim: No
Drug product claim: Yes
Assignee: Supernus Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.